Sherin Juliet Rouhani, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antigen Presentation | 3 | 2019 | 1252 | 0.410 |
Why?
|
Immunotherapy | 3 | 2024 | 4756 | 0.410 |
Why?
|
Endothelial Cells | 5 | 2019 | 3592 | 0.380 |
Why?
|
Lymph Nodes | 6 | 2022 | 3473 | 0.240 |
Why?
|
Antigens, CD | 1 | 2015 | 4032 | 0.230 |
Why?
|
Lymphatic Vessels | 3 | 2019 | 356 | 0.230 |
Why?
|
Dendritic Cells | 1 | 2015 | 2748 | 0.220 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2015 | 4413 | 0.200 |
Why?
|
Dermatitis | 1 | 2022 | 203 | 0.180 |
Why?
|
Immune Tolerance | 4 | 2015 | 2323 | 0.170 |
Why?
|
Adrenal Insufficiency | 1 | 2022 | 195 | 0.170 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2023 | 5434 | 0.170 |
Why?
|
Vaccines, Synthetic | 1 | 2022 | 622 | 0.160 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 710 | 0.150 |
Why?
|
Lung Neoplasms | 4 | 2023 | 13594 | 0.150 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2023 | 454 | 0.140 |
Why?
|
Arthritis | 1 | 2023 | 684 | 0.140 |
Why?
|
Antibody Formation | 1 | 2022 | 1393 | 0.140 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2015 | 4651 | 0.140 |
Why?
|
Neoplasms | 2 | 2023 | 22389 | 0.130 |
Why?
|
Saliva | 1 | 2021 | 854 | 0.130 |
Why?
|
Immunity, Cellular | 1 | 2022 | 1560 | 0.130 |
Why?
|
Cathepsin L | 1 | 2015 | 69 | 0.120 |
Why?
|
Hemagglutinins | 1 | 2015 | 111 | 0.120 |
Why?
|
Clonal Anergy | 1 | 2015 | 169 | 0.120 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 2015 | 318 | 0.120 |
Why?
|
Psoriasis | 1 | 2022 | 926 | 0.120 |
Why?
|
beta-Galactosidase | 1 | 2015 | 575 | 0.110 |
Why?
|
Endothelium, Lymphatic | 1 | 2014 | 63 | 0.110 |
Why?
|
Colitis | 1 | 2022 | 1242 | 0.110 |
Why?
|
Blood Vessels | 1 | 2019 | 1110 | 0.110 |
Why?
|
Fever | 1 | 2020 | 1619 | 0.110 |
Why?
|
Immunosuppressive Agents | 1 | 2024 | 4207 | 0.100 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2015 | 1439 | 0.090 |
Why?
|
Antibodies, Viral | 1 | 2022 | 3215 | 0.090 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2013 | 660 | 0.090 |
Why?
|
Vaccination | 1 | 2022 | 3438 | 0.080 |
Why?
|
Antigens | 1 | 2015 | 1444 | 0.080 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3859 | 0.080 |
Why?
|
Thrombosis | 1 | 2022 | 2956 | 0.080 |
Why?
|
Monophenol Monooxygenase | 3 | 2014 | 72 | 0.080 |
Why?
|
T-Lymphocytes | 3 | 2022 | 10276 | 0.070 |
Why?
|
Central Nervous System | 1 | 2015 | 1346 | 0.070 |
Why?
|
Bone Marrow Cells | 1 | 2015 | 2414 | 0.070 |
Why?
|
Mice, Transgenic | 3 | 2015 | 9565 | 0.070 |
Why?
|
Mice, Inbred C57BL | 5 | 2019 | 22379 | 0.070 |
Why?
|
Immunologic Memory | 1 | 2013 | 1378 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2021 | 5342 | 0.070 |
Why?
|
Melanoma | 1 | 2024 | 5709 | 0.060 |
Why?
|
Gene Expression | 2 | 2015 | 7603 | 0.060 |
Why?
|
Autoantibodies | 2 | 2023 | 2120 | 0.060 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3241 | 0.050 |
Why?
|
Mice | 7 | 2022 | 82072 | 0.050 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2022 | 325 | 0.050 |
Why?
|
Humans | 14 | 2024 | 768970 | 0.040 |
Why?
|
Adoptive Transfer | 2 | 2013 | 824 | 0.040 |
Why?
|
Cell Adhesion Molecules | 2 | 2019 | 1614 | 0.040 |
Why?
|
Signal Transduction | 4 | 2019 | 23653 | 0.040 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2021 | 239 | 0.040 |
Why?
|
Angiotensin II | 1 | 2022 | 844 | 0.040 |
Why?
|
Receptors, Interleukin-6 | 1 | 2020 | 224 | 0.040 |
Why?
|
Animals | 8 | 2022 | 169335 | 0.040 |
Why?
|
Immunity | 1 | 2023 | 1003 | 0.040 |
Why?
|
Diaphragm | 1 | 2019 | 357 | 0.040 |
Why?
|
Biological Specimen Banks | 1 | 2022 | 789 | 0.030 |
Why?
|
Epitopes | 1 | 2022 | 2529 | 0.030 |
Why?
|
Informed Consent | 1 | 2022 | 1010 | 0.030 |
Why?
|
Adrenal Cortex Hormones | 1 | 2024 | 1892 | 0.030 |
Why?
|
Cranial Sinuses | 1 | 2015 | 68 | 0.030 |
Why?
|
Immunologic Surveillance | 1 | 2015 | 93 | 0.030 |
Why?
|
Chemokines | 1 | 2019 | 963 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2020 | 965 | 0.030 |
Why?
|
Lymphotoxin beta Receptor | 1 | 2014 | 26 | 0.030 |
Why?
|
Mucoproteins | 1 | 2014 | 49 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 4592 | 0.030 |
Why?
|
Severity of Illness Index | 2 | 2022 | 15951 | 0.030 |
Why?
|
Meninges | 1 | 2015 | 197 | 0.030 |
Why?
|
Receptors, OX40 | 1 | 2012 | 46 | 0.030 |
Why?
|
RNA, Viral | 1 | 2021 | 2871 | 0.030 |
Why?
|
Mice, Knockout | 3 | 2014 | 14484 | 0.030 |
Why?
|
RNA | 1 | 2022 | 2727 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2012 | 2574 | 0.020 |
Why?
|
Viral Load | 1 | 2021 | 3398 | 0.020 |
Why?
|
Vitiligo | 1 | 2012 | 97 | 0.020 |
Why?
|
Extracellular Matrix | 1 | 2019 | 1739 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2022 | 4356 | 0.020 |
Why?
|
Anti-Inflammatory Agents | 1 | 2020 | 1811 | 0.020 |
Why?
|
Biopsy | 1 | 2023 | 6805 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2023 | 3671 | 0.020 |
Why?
|
MART-1 Antigen | 1 | 2010 | 62 | 0.020 |
Why?
|
Transcription Factors | 1 | 2010 | 12174 | 0.020 |
Why?
|
Protein Binding | 1 | 2022 | 9344 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 3952 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2023 | 81903 | 0.020 |
Why?
|
Glutamate Decarboxylase | 1 | 2010 | 239 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7214 | 0.020 |
Why?
|
Antigen-Presenting Cells | 1 | 2012 | 962 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 10765 | 0.020 |
Why?
|
Animals, Newborn | 1 | 2014 | 2683 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2023 | 11262 | 0.020 |
Why?
|
Cytokines | 1 | 2022 | 7453 | 0.020 |
Why?
|
Survival Rate | 1 | 2021 | 12873 | 0.020 |
Why?
|
Blood Pressure | 1 | 2022 | 8544 | 0.020 |
Why?
|
Databases, Factual | 1 | 2022 | 8094 | 0.020 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2010 | 827 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2024 | 65480 | 0.020 |
Why?
|
T-Lymphocyte Subsets | 1 | 2014 | 1813 | 0.020 |
Why?
|
Autoantigens | 1 | 2010 | 891 | 0.020 |
Why?
|
Disease Progression | 1 | 2023 | 13674 | 0.020 |
Why?
|
Male | 5 | 2023 | 365203 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2012 | 2635 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2010 | 1866 | 0.020 |
Why?
|
Female | 5 | 2023 | 397515 | 0.010 |
Why?
|
Stromal Cells | 1 | 2010 | 1337 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2023 | 9442 | 0.010 |
Why?
|
Lung | 1 | 2022 | 10099 | 0.010 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2010 | 1363 | 0.010 |
Why?
|
Middle Aged | 3 | 2023 | 223737 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8749 | 0.010 |
Why?
|
Antigens, Neoplasm | 1 | 2010 | 2001 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2010 | 6232 | 0.010 |
Why?
|
Prognosis | 1 | 2021 | 30046 | 0.010 |
Why?
|
B-Lymphocytes | 1 | 2014 | 4794 | 0.010 |
Why?
|
Autoimmune Diseases | 1 | 2012 | 2258 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2021 | 39394 | 0.010 |
Why?
|
Membrane Glycoproteins | 1 | 2010 | 3713 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2010 | 5505 | 0.010 |
Why?
|
Time Factors | 1 | 2020 | 40261 | 0.010 |
Why?
|
Aged | 2 | 2021 | 171786 | 0.010 |
Why?
|
Mutation | 1 | 2023 | 30266 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2010 | 3608 | 0.010 |
Why?
|
Adult | 2 | 2021 | 223851 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2021 | 59739 | 0.010 |
Why?
|
Phenotype | 1 | 2014 | 16731 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2010 | 10486 | 0.010 |
Why?
|